Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025 RSV vaccine Abrysvo specifically ... for profit margin expansion, buoyed by commercial execution and cost-savings efforts ...

GSK has been the dominant player in the RSV vaccine market since Arexvy first gained approval in 2023, although Pfizer has made inroads into its market share. While initial launches for both ...

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

A year after making its Super Bowl commercial debut, Pfizer is back with a 60-second spot for the 2025 game featuring a kid fighting cancer like a boxing champion. Set to LL Cool J's "Mama Said ...

Pfizer management say its key focus areas include improving R&D productivity, expanding margins, achieving commercial excellence ... a vaccine against RSV, which will generate revenues of ...

Are you a print subscriber? Activate your account. By Mike Lacey - 1 hour 1 min ago By Tim Nudd - 1 hour 27 min ago By Garett Sloane - 5 hours 15 min ago By Jon Springer - 8 hours 45 min ago 8 ...